Total trials
804
Active
141
Phase 3
51
Total enrollment
19,885,634
Pipeline matrix
Showing 40 of 123 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Aspirin | — | — | — | — | 3 | ||
| Tafenoquine | — | — | — | — | — | 2 | |
| PCV15 | — | — | — | — | — | 1 | |
| Streptococcus pneumoniae serotype 3 | — | — | — | — | — | 1 | |
| Artemether 20 mg-Lumefantrine 120 mg | — | — | — | — | — | 1 | |
| Daridorexant 50 mg | — | — | — | — | — | 1 | |
| Omega-3 Ethyl Esters | — | — | — | — | — | 1 | |
| Doxycycline 7 days | — | — | — | — | — | 1 | |
| Doxycycline 3 days | — | — | — | — | — | 1 | |
| Azithromycin 3 days | — | — | — | — | — | 1 | |
| 10μg R21/50μg Matrix-M | — | — | — | — | — | 1 | |
| 5μg R21/50μg Matrix-M with adaptor preservative free | — | — | — | — | — | 1 | |
| 5μg R21/50μg Matrix-M with 2PE preservative | — | — | — | — | — | 1 | |
| DHA/piperaquine and a SLD-PQ | — | — | — | — | — | 1 | |
| Study vaccine R21/Matrix-M™ | — | — | — | — | — | 1 | |
| Semaglutide Oral | — | — | — | — | — | 1 | |
| Chloroquine | — | — | — | 7 | |||
| Molnupiravir | — | — | — | — | 4 | ||
| Oseltamivir | — | — | — | 4 | |||
| Hydroxychloroquine | — | — | — | — | 2 | ||
| Sotrovimab | — | — | — | — | 2 | ||
| CBD 100 mg/mL Oral Solution | — | — | — | — | — | 2 | |
| Azithromycin | — | — | — | — | — | 2 | |
| R21/Matrix-M | — | — | — | — | 2 | ||
| Anacetrapib | — | — | — | — | — | 1 | |
| Rabies vaccine, Hepatitis A vaccine or Meningococcal vaccine | — | — | — | — | — | 1 | |
| Placeb | — | — | — | — | — | 1 | |
| Inclisiran | — | — | — | — | — | 1 | |
| Lopinavir-Ritonavir | — | — | — | — | — | 1 | |
| Corticosteroid | — | — | — | — | — | 1 | |
| Convalescent plasma | — | — | — | — | — | 1 | |
| Tocilizumab | — | — | — | — | — | 1 | |
| Immunoglobulin | — | — | — | — | — | 1 | |
| Synthetic neutralising antibodies | — | — | — | — | — | 1 | |
| Colchicine | — | — | — | — | — | 1 | |
| Baricitinib | — | — | — | — | — | 1 | |
| Anakinra | — | — | — | — | — | 1 | |
| Dimethyl fumarate | — | — | — | — | — | 1 | |
| High Dose Corticosteroid | — | — | — | — | — | 1 | |
| Empagliflozin | — | — | — | — | — | 1 |
83 more active programs hidden
Next readouts
- 2017-01-31
- 2018-03-12
- 2023-02-16
- 2023-03-21
- 2025-07
- 2025-07
- 2025-08-05
- 2025-08-15
- 2025-09
- 2025-10-01
Top conditions
- Malaria60
- Tuberculosis31
- Depression29
- Healthy23
- Malaria,Falciparum15
- Influenza12
- Vivax Malaria10
- Plasmodium Falciparum Malaria10
Frequently asked questions about University of Oxford
- How many clinical trials does University of Oxford have on ClinicalTrials.gov?
- University of Oxford is listed as the lead sponsor on 804 clinical trials in ClinicalTrials.gov, 141 of which are currently active (recruiting, enrolling, or ongoing).
- How many of University of Oxford's trials are in Phase 3?
- 51 of University of Oxford's trials are in Phase 3, spread across 123 active drug programs.
- What therapeutic areas does University of Oxford focus on?
- University of Oxford's most-studied conditions on ClinicalTrials.gov are Malaria, Tuberculosis, Depression, Healthy, Malaria,Falciparum.
- When are University of Oxford's next clinical trial readouts?
- University of Oxford has 10 upcoming primary-completion readouts tracked here; the soonest is “REVEAL: Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification”, expected around 2017-01-31.